← All trials
NCT02732587
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- Mar 15, 2016
- Completion date
- Mar 23, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityReponsible party - principal investigator
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.